Drug intelligence / Profile preview

conatumumab + ganitumab

Development stage: Phase 2
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Conatumumab + ganitumab is a combination therapy consisting of two monoclonal antibodies with different mechanisms of action. Conatumumab is an agonistic monoclonal antibody that targets death receptor 5 (DR5), promoting apoptosis in cancer cells. Ganitumab is an antagonistic monoclonal antibody that targets the type 1 insulin-like growth factor receptor (IGF-1R), inhibiting cancer cell growth and survival pathways. This combination has been investigated for the treatment of various advanced solid tumors, including colorectal cancer, pancreatic cancer, and other malignancies.

Other names: ganitumab + conatumumabIGF1R antibody (ganitumab) + DR5 agonist antibody (conatumumab)

Targets

TNFRSF10B (DR5)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on conatumumab + ganitumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on conatumumab + ganitumab.